<DOC>
	<DOCNO>NCT00160134</DOCNO>
	<brief_summary>The study randomize , placebo control , multi-center , single dose study evaluate cardiac hemodynamics safety iv SLV320 110 subject congestive heart failure require diuretic treatment . Each subject receive one dose SLV320 placebo furosemide . The study consist three visit ( study day in-subjects include ) . Ambulatory subject hospital two night one day .</brief_summary>
	<brief_title>Study Evaluate Cardiac Hemodynamics Safety SLV320 Subjects With Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>history chronic , symptomatic , mild severe ( NYHA Class IIIV ) CHF least three month require treatment diuretic document systolic dysfunction stable dos individually optimize medication regimen least one week prior enrollment require hospitalization ( cardiovascular disease ) adjustment background medication CHF orthostatic hypotension symptomatic orthostasis sit systolic diastolic blood pressure &lt; 90 mmHg 2nd 3rd degree atrioventricular block sick sinus syndrome heart rate &lt; 50 &gt; 110 bpm ECG transplant heart heart failure due primary valvular disease ( unless surgically correct ) , obstructive cardiomyopathy , pericardial disease , cor pulmonale congenital heart disease hemodynamically significant leave ventricular outflow tract obstruction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>congestive heart failure , adenosine receptor blocker , cardiac hemodynamic</keyword>
</DOC>